Vietnam drug spending makes it a prime pharma target

Last year Sanofi ($SNY) boss Chris Viehbacher ran out his list of his favorite emerging market opportunities including Colombia, Indonesia and Vietnam. A new rundown on recent developments in Vietnam, show the many reasons why Viehbacher would see the southeast Asian country as a very good bet.

It is one of the fastest growing global markets in drug spending, placing 13 of 175 on a Business Monitor International ranking, points out Ames Gross, president of Pacific Bridge Medical, a Bethesda, MD-based consulting firm that specializes in Asia. His piece in pharmaphorum says drug spending there should grow at a rate of 20% through 2017. And per capita drug spending is only going to go up. In 2010, he said it was already $104 anually, twice that of India. That will increase with an expanding economy and health system. By 2020, 90% of Vietnamese are expected to be covered by the national health system, up from 65% today.

Some drugmakers are already tapping that potential. GlaxoSmithKline ($GSK) since 2010 has had a deal with Savipharm, a leading Vietnamese pharmaceutical company. Japan's Nipro Pharma last year invested $250 million to build it own manufacturing plant there. Stada has taken a different approach and now owns nearly half of Vietnamese drug maker Pymepharco.

In fact, Gross points out that while foreign drugmakers had been barred from setting up wholly-owned subsidiaries in Vietnam, they are now permitted, although they must also establish a manufacturing facility to do so.

Vietnam was only one of a number of countries that Sanofi's Viehbacher mentioned. And three weeks after discussing targets, the company swooped in and snatched up Genfar, the second-largest generics maker in Colombia.

- here's the report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.